OBJECTIVES: The study aims to examine the extent to which the updated ACC/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians' adherence the guidelines recommendations. METHODS: We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists' interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy. RESULTS: Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p<0.0001) and from 0.0% to 1.6% (X2 = 6, p = 0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2 = 19.2, p<0.0001). CONCLUSION: Collaboration between physicians and clinical pharmacists is a crucial strategy to improve patients' treatment and hence, achieve better health outcomes among patients suffering from dyslipidemia.

AAU Health and Biomedical Research Center Al Ain University Abu Dhabi United Arab Emirates

Czech Rehabilitation Hospital Al Ain United Arab Emirates

Department of Biopharmaceutics and Clinical Pharmacy School of Pharmacy University of Jordan Amman Jordan

Department of Clinical Pharmacy College of Pharmacy Al Ain University Al Ain United Arab Emirates

Department of Pharmacology and Therapeutics College of Medicine and Health Sciences United Arab Emirates University Al Ain United Arab Emirates

Mediclinic AlAin Hospital Al Ain United Arab Emirates

Zobrazit více v PubMed

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, et al.. (2022) Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation 145: e153–e639. doi: 10.1161/CIR.0000000000001052 PubMed DOI

World Health Organization (WHO). Cardiovascular diseases (CVDs). [Internet] Geneva: WHO; 2021. [updated 2021 June 11, cited 2022 Sept 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

Li Z, Lin L, Wu H, Yan L, Wang H, et al.. (2021) Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention. Front Public Health 9: 559751. doi: 10.3389/fpubh.2021.559751 PubMed DOI PMC

Mahmoud I, Sulaiman N (2019) Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study. BMJ Open 9: e031969. doi: 10.1136/bmjopen-2019-031969 PubMed DOI PMC

Sulaiman N, Elbadawi S, Hussein A, Abusnana S, Madani A, et al.. (2017) Prevalence of overweight and obesity in United Arab Emirates Expatriates: the UAE National Diabetes and Lifestyle Study. Diabetol Metab Syndr 9: 88. doi: 10.1186/s13098-017-0287-0 PubMed DOI PMC

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, et al.. (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63: 2889–2934. doi: 10.1016/j.jacc.2013.11.002 PubMed DOI

Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, et al.. (2019) Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73: 3210–3227. doi: 10.1016/j.jacc.2018.11.004 PubMed DOI

Grundy SM, Stone NJ (2019) 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. JAMA Cardiol 4: 589–591. doi: 10.1001/jamacardio.2019.0911 PubMed DOI

Underberg J, Toth PP, Rodriguez F (2022) LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgraduate Medicine. doi: 10.1080/00325481.2022.2117498 PubMed DOI

Gitt AK, Parhofer KG, Laufs U, März W, Paar WD, et al.. (2022) Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. Clinical Research in Cardiology: 1–13. doi: 10.1007/s00392-022-02108-w PubMed DOI

Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, et al.. (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129: S49–73. doi: 10.1161/01.cir.0000437741.48606.98 PubMed DOI

Rosenson RS (2016) Statin non-adherence: clinical consequences and proposed solutions. F1000Res 5. doi: 10.12688/f1000research.8215.1 PubMed DOI PMC

Nguyen PV, Biron P (2015) Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. J Am Coll Cardiol 65: 2768–2769. doi: 10.1016/j.jacc.2015.02.083 PubMed DOI

Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, et al.. (2002) A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 162: 1149–1155. doi: 10.1001/archinte.162.10.1149 PubMed DOI

Yun H, Safford MM, Brown TM, Farkouh ME, Kent S, et al.. (2015) Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction. J Am Heart Assoc 4. doi: 10.1161/JAHA.114.001208 PubMed DOI PMC

Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G (2011) Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 171: 1441–1453. doi: 10.1001/archinternmed.2011.399 PubMed DOI

Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR (2008) Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 42: 1195–1207. doi: 10.1345/aph.1K618 PubMed DOI

George J, McNamara K, Stewart K (2011) The roles of community pharmacists in cardiovascular disease prevention and management. Australas Med J 4: 266–272. doi: 10.4066/AMJ.2011.698 PubMed DOI PMC

Dunn SP, Birtcher KK, Beavers CJ, Baker WL, Brouse SD, et al.. (2015) The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol 66: 2129–2139. doi: 10.1016/j.jacc.2015.09.025 PubMed DOI

Bedi O, Dhawan V, Sharma PL, Kumar P (2016) Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 389: 695–712. doi: 10.1007/s00210-016-1252-4 PubMed DOI

Yoshida T, Hayashi M (2017) Pleiotropic effects of statins on acute kidney injury: involvement of Kruppel-like factor 4. Clin Exp Nephrol 21: 175–181. doi: 10.1007/s10157-016-1286-4 PubMed DOI

Mohammad S, Nguyen H, Nguyen M, Abdel-Rasoul M, Nguyen V, et al.. (2019) Pleiotropic Effects of Statins: Untapped Potential for Statin Pharmacotherapy. Curr Vasc Pharmacol 17: 239–261. doi: 10.2174/1570161116666180723120608 PubMed DOI

Bozovich M, Rubino CM, Edmunds J (2000) Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 20: 1375–1383. doi: 10.1592/phco.20.17.1375.34895 PubMed DOI

Tahaineh L, Albsoul-Younes A, Al-Ashqar E, Habeb A (2011) The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan. Int J Clin Pharm 33: 229–236. doi: 10.1007/s11096-011-9479-0 PubMed DOI

Tsuyuki RT, Rosenthal M, Pearson GJ (2016) A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott) 149: 283–292. doi: 10.1177/1715163516662291 PubMed DOI PMC

Doellner JF, Dettloff RW, DeVuyst-Miller S, Wenstrom KL (2017) Prescriber acceptance rate of pharmacists’ recommendations. J Am Pharm Assoc (2003) 57: S197–S202. doi: 10.1016/j.japh.2017.03.002 PubMed DOI

Meredith AH, Ramsey D, Schmelz A, Berglund R (2019) Resident physicians’ perceptions of ambulatory care pharmacy. Pharm Pract (Granada) 17: 1509. doi: 10.18549/PharmPract.2019.3.1509 PubMed DOI PMC

Ganga HV, Slim HB, Thompson PD (2014) A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168: 6–15. doi: 10.1016/j.ahj.2014.03.019 PubMed DOI

Cohen JD, Brinton EA, Ito MK, Jacobson TA (2012) Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6: 208–215. doi: 10.1016/j.jacl.2012.03.003 PubMed DOI

Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, et al.. (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Jama 308: 2497–2506. doi: 10.1001/jama.2012.25790 PubMed DOI

Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, et al.. (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63: 2541–2548. doi: 10.1016/j.jacc.2014.03.019 PubMed DOI

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, et al.. (2015) Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9: 758–769. doi: 10.1016/j.jacl.2015.08.006 PubMed DOI

Aburuz S, Al-Bekairy A, Alqahtani AA, Harbi K, Al Nuhait M, et al.. (2018) Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia. J Saudi Heart Assoc 30: 349–355. doi: 10.1016/j.jsha.2018.08.003 PubMed DOI PMC

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, et al.. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372: 2387–2397. doi: 10.1056/NEJMoa1410489 PubMed DOI